6-(Piperidin-4-yl)indolin-2-one | 1138217-92-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 6-(Piperidin-4-yl)indolin-2-one
• 英文别名: 6-piperidin-4-yl-1,3-dihydroindol-2-one
• CAS: 1138217-92-1
• 化学式: C₁₃H₁₆N₂O
• 分子量: 216.283
• InChiKey: OKNXVFPVIXCNIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(Piperidin-4-yl)indolin-2-one 、 C₁₇H₁₆ClFN₂ 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 6-(1-(4-(1-(4-fluorophenyl)-1H-benzo[d]imidazol-2-yl)butyl)piperidin-4-yl)indolin-2-one
  参考文献：
  名称：

  Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists

  摘要：

  Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays role in several disorders such as obesity, stress, depression and anxiety. The synthesis and biological evaluation of novel benzimidazole derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.086
• 作为产物：
  描述：

  tert-butyl 4-(2-oxo-2,3-dihydro-1H-indol-6-yl)piperidine-1-carboxylate 在 盐酸 、 氨 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 6-(Piperidin-4-yl)indolin-2-one
  参考文献：
  名称：

  Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists

  摘要：

  Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays role in several disorders such as obesity, stress, depression and anxiety. The synthesis and biological evaluation of novel benzimidazole derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.086

文献信息

• DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR
  申请人：Ando Makoto

  公开号：US20100324049A1

  公开（公告）日：2010-12-23

  [Problems] To provide an antagonist of a melanin-concentrating hormone receptor, which is useful as a medicine for a central nervous system disease, a cardiovascular disease or a metabolic disease. [Means for Solving Problems] The antagonist comprises, as an active ingredient, a compound represented by the formula (I) wherein R 1a and R 1b independently represent a hydrogen atom or a C 1-6 alkyl group; R 2a , R 2b , R 3a and R 3b independently represent a hydrogen atom, a C 1-6 alkyl group, or the like; Y represents H or —OH; Z represents —OR 8 , or the like; R 8 represents a hydrogen atom, a C 1-6 alkyl group which may have a substituent, or the like; R 9a and R 9b independently represent a hydrogen atom, a C 1-6 alkyl group, or the like; Ar 1 represents an aromatic carbon ring group, or an aromatic heteroring group; Ar 2 represents a group produced by removing two hydrogen atoms from an aromatic carbon ring, or the like; and the ring group A represents an unsaturated heteroring group.

  [问题] 提供一种黑素浓集激素受体的拮抗剂，该拮抗剂作为治疗中枢神经系统疾病、心血管疾病或代谢疾病的药物是有用的。 [解决问题的手段] 该拮抗剂包含作为活性成分的以下公式（I）所示的化合物： 其中 R1a 和 R1b 分别独立代表一个氢原子或一个C1-6烷基团；R2a、R2b、R3a 和 R3b 分别独立代表一个氢原子、一个C1-6烷基团或类似物；Y代表H或—OH；Z代表—OR8，或类似物；R8代表一个氢原子、一个可能含有取代基的C1-6烷基团或类似物；R9a和R9b分别独立代表一个氢原子、一个C1-6烷基团或类似物；Ar1代表一个芳香碳环族或芳香杂环族；Ar2代表通过从一个芳香碳环中移除两个氢原子而得到的族或类似物；而环族A代表一个不饱和杂环族。
• Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists
  作者：Pradip K. Sasmal、Sanjita Sasmal、P. Tirumala Rao、B. Venkatesham、M. Roshaiah、Chandrasekhar Abbineni、Ish Khanna、Vikram P. Jadhav、J. Suresh、Rashmi Talwar、Syed Muzeeb、Jean-Marie Receveur、Thomas M. Frimurer、Øystein Rist、Lisbeth Elster、Thomas Högberg

  DOI：10.1016/j.bmcl.2010.07.086

  日期：2010.9

  Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays role in several disorders such as obesity, stress, depression and anxiety. The synthesis and biological evaluation of novel benzimidazole derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. (c) 2010 Elsevier Ltd. All rights reserved.